Journal of Medical Economics
Volume 27, 2024 - Issue 1
Cardiovascular
Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes
Dina Abushanaba Department of Pharmacy, Hamad Medical Corporation, Doha, Qatar
https://orcid.org/0000-0002-4162-8617
https://orcid.org/0000-0002-4162-8617, , Rasha Kaddouraa Department of Pharmacy, Hamad Medical Corporation, Doha, Qatarhttps://orcid.org/0000-0003-2613-9759
https://orcid.org/0000-0003-2613-9759, Moza Al Haila Department of Pharmacy, Hamad Medical Corporation, Doha, Qatarhttps://orcid.org/0000-0003-4991-982X
https://orcid.org/0000-0003-4991-982X, Palli Valappila Abdul Roufa Department of Pharmacy, Hamad Medical Corporation, Doha, Qatarhttps://orcid.org/0000-0002-6924-8245
https://orcid.org/0000-0002-6924-8245, Wessam El Kassema Department of Pharmacy, Hamad Medical Corporation, Doha, Qatarhttps://orcid.org/0000-0003-2145-7555
https://orcid.org/0000-0003-2145-7555, , & Daoud Al-Badriyehc College of Pharmacy, QU Health, Qatar University, Doha, QatarCorrespondence[email protected]
https://orcid.org/0000-0001-7791-954X
https://orcid.org/0000-0001-7791-954X show all